Shared on 01 Nov 25
Fair value Decreased 0.60%The analyst price target for Tecan Group has been revised downward from CHF 177 to CHF 170. Analysts cite slightly softer revenue growth expectations and a modest increase in the discount rate in their updated assessments.
Shared on 18 Oct 25
Fair value Decreased 3.94%Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Tecan Group's updated analyst fair value price target has been revised downward from CHF 215.73 to CHF 207.23. This change reflects cautious analyst views amid slower revenue growth and tightened profit margin expectations.
Shared on 04 Oct 25
Fair value Decreased 2.15%Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Analysts have adjusted their price target for Tecan Group downward, reducing the fair value estimate from CHF 220.47 to CHF 215.73. This change is due to a slight increase in the discount rate, although forecasts for revenue growth and profit margins have improved.
Shared on 05 Sep 25
Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Analysts have lowered their outlook for Tecan Group due to concerns over near-term margin pressure, cautious end-market demand, and delayed recovery in key segments, though the consensus price target remained unchanged at CHF220.47. Analyst Commentary Cautious sentiment due to anticipation of "soft" first-half financial results impacting near-term performance.
Shared on 01 May 25
Fair value Decreased 7.95%Advanced Automation And Personalized Medicine Will Shape Healthcare's Future
Shared on 23 Apr 25
Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 0.083%Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 6.53%Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
AnalystConsensusTarget made no meaningful changes to valuation assumptions.